REALITY delayed
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis will announce results of its REALITY trial, comparing Cypher sirolimus-eluting stents with Boston Scientific Taxus paclitaxel-eluting stents, at the American College of Cardiology meeting in March in Orlando, instead of at the November American Heart Association meeting in New Orleans, as previously planned, the firm announced Sept. 14 (1"The Gray Sheet" May 10, 2004, p. 6)...
You may also be interested in...
Cypher, Taxus Perform Equally Well In Trials, Registries – Meier Analysis
The overall clinical performance of Boston Scientific's Taxus and J&J/Cordis' Cypher drug-eluting coronary stents is practically equivalent, according to Bernard Meier, MD, University Hospital, Bern, Switzerland
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.